News | March 28, 2007

Physicians Seeing Recovery of Dead Heart Tissue with Stem Cell Procedure

March 29, 2007 — At the ACC this week Dr. Nabil Dib, M.D., M.Sc., director of Cardiovascular Cell Therapy at University of California San Diego, reported how 23 patients in an FDA trial were safely transformed from advanced heart failure to recovery.

Author and researcher Christian Wilde has spent seven years studying preventive cardiovascular detection and treatment and has worked with Dr. Nabil Dib extensively in preparing his second breakthrough book, “Miracle Stem Cell Heart Repair,” This procedure proves for the first time in medical history that dead heart tissue can now be safely clinically repaired. It signifies hope for 22 million patients worldwide currently dying of congestive heart failure.

The book documents case histories and personal journeys of many of Dr. Dib's patients, as well as patients from other ongoing FDA trial successes who have undergone the one time minimally invasive procedure.

Many of Dr. Dib's patients in the trial have had four and even five previous heart attacks, which led them into heart failure. Many also presented with recorded ejection fractions (a measurement of the left ventricle's ability to pump blood) in the very low teens, 20s and 30s. Normal ejection fraction is between 50-70.

Until now, cardiologists have only been able to offer drugs, pacemakers and defibrillators as "band-aids" in treating advancing congestive heart failure. CHF patients may very soon have another promising long-term viable alternative in adult stem cell therapy — cells that the body will not reject and that do not cause tumor development.

Related Content

Placental Stem Cells Can Regenerate the Heart After Heart Attack
News | Stem Cell Therapies | May 20, 2019
Researchers at the Icahn School of Medicine at Mount Sinai have demonstrated that stem cells derived from the placenta...
ProxiCor Extracellular Matrix Reduces Complications, Readmissions Following Pericardial Reconstruction
News | Stem Cell Therapies | April 19, 2019
Aziyo Biologics Inc. announced the publication of results from its landmark RECON study in the Journal of...
FDA Releases Final Guidances on Regenerative Medicine Therapies
News | Stem Cell Therapies | March 04, 2019
The U.S. Food and Drug Administration (FDA) recently finalized two guidance documents regarding regenerative medicine...
Heart Muscle Cells Created From Stem Cells Beat in Sync
News | Stem Cell Therapies | February 01, 2019
A team of Rutgers scientists have taken an important step toward the goal of making diseased hearts heal themselves – a...
FDA Clamps Down on Unapproved Stem Cell Therapies
News | Stem Cell Therapies | December 20, 2018
December 20, 2018 — The U.S.
Secant Introduces First Synthetic Regenerative Cardiovascular Graft for CABG
News | Stem Cell Therapies | January 17, 2018
Secant Group, in partnership with its sister company SanaVita Medical, announced new technology to advance...
News | Stem Cell Therapies | October 24, 2017
October 24, 2017 — Roche and Ncardia have reached a broad licensing agreement whereby Roche and its affiliate compani
BioCardia Announces 12-Month Results from TRIDENT Trial of Stem Cell Delivery System
News | Stem Cell Therapies | September 26, 2017
BioCardia Inc. recently announced 12-month results from the Phase II TRIDENT clinical trial, conducted by the...
New Jersey Researcher Exploring New Stem Cell Therapies for Heart Attacks
News | Stem Cell Therapies | August 04, 2017
In petri dishes in her campus laboratory at New Jersey Institute of Technology, Alice Lee is developing colonies of...
Overlay Init